Lab Rats to Unicorns

John Flavin

Lab Rats to Unicorns is a podcast that aims to demystify the process of creating a great company in life sciences. Under the guidance of our host, John Flavin, you will hear personal stories of creation, be able to understand how great companies are created, and get insights into the many ways that you as an individual can engage in the creation of tomorrow’s life science companies. From the lab rat, signifying the process of invention and discovery, to the unicorn, signifying market success, there are a thousand players and ways in which people can contribute to the creation of great companies.

  1. The CEO Playbook for Biotech Growth with Heather Turner_e.085

    3d ago

    The CEO Playbook for Biotech Growth with Heather Turner_e.085

    In this episode of Lab Rats to Unicorns, John Flavin sits down with Heather Turner, CEO of LB Pharmaceuticals, a late-stage clinical biotechnology company developing differentiated therapies for patients with serious psychiatric and neurological disorders. Heather’s path into biotech was anything but traditional. Trained as an attorney, she began her career advising startup companies at Cooley before spending more than two decades helping build and scale life sciences companies through financings, strategic partnerships, and major transactions. Along the way, she developed a unique perspective on leadership, risk management, and company building—eventually transitioning from legal leadership roles into the CEO seat. The conversation explores Heather’s journey from lawyer to biotech executive, the lessons learned leading Carmot Therapeutics through a $3.1 billion acquisition by Roche, and the challenges of raising capital in one of biotech’s most difficult financing environments. She also shares how LB Pharmaceuticals successfully completed a public offering to advance its lead program, LB-102, a potential new treatment for schizophrenia, bipolar depression, and major depressive disorder. At its core, this episode is about leadership in uncertainty—how great companies are built through preparation, resilience, humility, and a relentless focus on patients. Heather offers valuable insights on scaling organizations, building high-performing teams, navigating risk, and creating opportunities for the next generation of biotech leaders.

    51 min
  2. Powering the Quantum Revolution with David Gunnarsson_e.084

    Jun 3

    Powering the Quantum Revolution with David Gunnarsson_e.084

    In this episode of Lab Rats to Unicorns, John Flavin sits down with Dr. David Gunnarsson, Chief Business Development Officer at Bluefors, the global leader in cryogenic measurement systems powering the future of quantum technology. With a background spanning quantum physics, low-temperature research, and commercialization, David has spent his career helping transform quantum computing from a theoretical concept into an emerging industry. David reflects on his early fascination with physics and space, his introduction to quantum computing during university, and the realization that quantum mechanics could evolve from pure theory into a practical technology. He explains the fundamentals of quantum computing, why cryogenic environments are essential for quantum systems, and how companies like Bluefors are building the infrastructure required to scale the field. The conversation also explores David’s transition from academia into industry, the importance of timing and commercialization in deep tech, and how collaboration between startups, universities, and major companies is shaping the quantum ecosystem. Along the way, he shares his perspective on the relationship between AI and quantum computing, and why the next decade could unlock major breakthroughs in chemistry, drug discovery, and computational science. At its core, this episode is about curiosity, persistence, and the challenge of turning frontier scientific ideas into technologies capable of reshaping the world.

    51 min
  3. CRISPR Discovery & Curative Medicine with Trevor Martin_e.083

    May 7

    CRISPR Discovery & Curative Medicine with Trevor Martin_e.083

    In this episode of Lab Rats to Unicorns, John Flavin sits down with Dr. Trevor Martin, Co-Founder and CEO of Mammoth Biosciences, a company at the forefront of next-generation CRISPR technologies. Co-founded alongside Nobel Prize-winning scientist Jennifer Doudna, Mammoth is building a platform to both detect and cure disease by harnessing the natural diversity of CRISPR systems. Trevor’s journey into biology was anything but conventional—initially drawn to physics and chemistry, he discovered biology through an interdisciplinary lens that revealed its true complexity and potential for engineering. That shift ultimately led him to Stanford, where he began exploring the intersection of genetics, computation, and real-world impact. From there, this conversation traces the founding of Mammoth, the decision to pursue entrepreneurship over academia, and the ambition to build a generational biotech company—not just a single-asset success. Trevor shares how CRISPR is evolving from a breakthrough technology into a scalable platform capable of addressing a wide range of genetic diseases, with the potential to fundamentally reshape human health. At its core, this episode explores the convergence of science, entrepreneurship, and persistence—highlighting what it takes to translate cutting-edge research into real therapies, and why the next decade of biology may redefine what it means for genetics to determine our future.

    50 min

Ratings & Reviews

5
out of 5
16 Ratings

About

Lab Rats to Unicorns is a podcast that aims to demystify the process of creating a great company in life sciences. Under the guidance of our host, John Flavin, you will hear personal stories of creation, be able to understand how great companies are created, and get insights into the many ways that you as an individual can engage in the creation of tomorrow’s life science companies. From the lab rat, signifying the process of invention and discovery, to the unicorn, signifying market success, there are a thousand players and ways in which people can contribute to the creation of great companies.

You Might Also Like